A phase 2 clinical trial with the IDO inhibitor indoximod (NLG-8189, 1-Methyl-D-tryptophan) (NCT01560923) provided significant evidence of the efficacy of indoximod as an immunometabolic adjuvant in combination with the DC vaccine sipuleucel-T (Provenge®) in advanced PCa [334]. This evidence concerns the gene IDO1 and posterior cortical atrophy.